AGM statement & positive Q1 trading update
Summary by AI BETAClose X
EKF Diagnostics Holdings plc
("EKF" or the "Company")
AGM Statement
& Positive Q1 Trading update
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, provides an update to shareholders ahead of its Annual General Meeting ('AGM') today at Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD at 11.00 am.
Executive Chair's AGM statement
We are very pleased that trading to date for the year ended 31 December 2026 ("FY 2026") remains in-line with management expectations. As usual, we will provide an unaudited trading update for first six months of the current financial year ("H1 2026") at the end of July.
The completion of the first year of our Five-Year Strategic Development plan has firmly re-established the business with a simplified product offering, a greater commercial focus on the areas of strategic importance and an expanded marketing team to drive further organic growth.
Operational cash generation continues to be very strong alongside the continued internal investment for growth and the ongoing share buyback programme. Cash position as of 8 May is £15.0m, with £2.1m held by our Russian subsidiary and subject to regulatory restrictions, and we will continue to invest in areas that will further build on our growth strategy, and deliver long term shareholder value.
Commercial traction for Hematology remains strong with good ongoing instrument placement and increased consumable pull-through as expected. Within the Life Sciences division, β-HB sales have performed above management expectations and the pipeline and prospects for our contract fermentation services continues to grow showing continued steady improvement.
We remain excited about the prospects for the business and are on track to deliver growth at the revenue and adjusted EBITDA1 levels for FY 2026 in-line with market expectations2.
1adjusted earnings before interest, tax, depreciation and amortisation, share-based payments and exceptional items
²Management understands consensus revenue and Adjusted EBITDA forecasts for FY 2026 to be £54.6m and £13.6m respectively.
|
EKF Diagnostics Holdings plc |
||
|
Julian Baines, Executive Chair / Gavin Jones, Chief Executive Officer |
via Walbrook PR |
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: +44 (0)20 7496 3000 |
|
|
Phil Davies / Patrick Weaver |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
|
● |
Point-of-Care analysers in the key areas of Hematology and Diabetes |
|
● |
Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. |
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 11 hours ago Johnson Matthey
- 12 hours ago Galliford Try
- 12 hours ago Galliford Try
- 12 hours ago Centrica
- 13 hours ago Smith & Nephew